BIOTRON LIMITED (ASX:BIT) - COVID19 - competitive landscape, page-2 - HotCopper | ASX Share Prices, Stock Market & Share Trading Forum

Originally posted by shareman: ↑

Long term, I really hope BIT’s pre-clinical antiviral portfolio proves valuable.

However, in my view, it is unlikely that BIT will have a big (or any) role to play in the current pandemic.

Even if they get a positive hit for SARS-CoV-2 in a lab, this is likely a very long way off (especially if the hits only involve compounds other than BIT225) from having a commercialised product able to treat COCID-19 patients in the clinic. If BIT announces a positive hit in the lab for SARS-CoC-2, no doubt some people will rush in and reflexively buy and there will be a spike in the share price.

Unless the results are beyond spectacular, it is likely the share price will drift downwards after this spike (as it has done countless times in the past) as:
- traders exit
- people realise the competition in the COVID-19 treatment space is enormous; and
- it becomes clear the probability of BIT commercialising a product for the current pandemic is low at best.

For long-term value investors, it is always critically important to understand the competitive landscape before making an investment decision. Below is a small fraction of the many treatments under development for COVID-19 that current and prospective long-term BIT investors should make themselves familiar with.

No doubt if you went to the local stock market message boards (i.e. hotcopper equivalents) in the various countries where these companies are based, posters/traders/rampers would be writing just as confidently about how “company X” is a sure thing as posters on hotcopper do about BIT.

1. https://ir.moleculin.com/press-releases/detail/162/moleculin-announces-active-compound-in-wp1122-reduces

2. https://www.abcellera.com/news/2020-03-abcellera-and-lilly-codevelopment

3. https://www.prnewswire.com/news-releases/fda-clears-the-way-for-ridgeback-biotherapeutics-to-begin-human-testing-of-a-promising-potential-treatment-for-covid-19-301036307.html

4. https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-important-advances-novel-covid-19-antibody

5. http://www.oyageninc.com/wordpress/wp-content/uploads/2020/03/OyaGen-Press-for-03102020.pdf

6. https://investors.vir.bio/news-releases/news-release-details/samsung-biologics-and-vir-biotechnology-enter-agreement-large

7. https://investors.alnylam.com/press-release?id=24656

8. https://www.wsj.com/articles/supercomputers-help-researchers-speed-drug-discovery-for-covid-19-11586888735

9. https://www.immunic-therapeutics.com/2020/04/21/immunic-inc-reports-that-imu-838-a-selective-oral-dhodh-inhibitor-has-demonstrated-preclinical-activity-against-sars-cov-2-and-explores-plans-for-a-phase-2-clinical-trial-in-covid-19-patients/

10. https://www.beronigroup.com/2020/03/13/beroni-group-advances-research-and-development-of-medical-solution-for-coronavirus-covid-19/

11. https://www.beyondspringpharma.com/pressreleases/info.aspx?itemid=2212

12. https://www.cocrystalpharma.com/news/press-releases/detail/91/cocrystal-pharma-expands-exclusive-license-agreement-with

13. https://www.distributedbio.com/covid19

14. https://www.enanta.com/investors/news-releases/press-release/2020/Enanta-Pharmaceuticals-Announces-Efforts-to-Discover-a-Treatment-for-the-Novel-Coronavirus-Disease-COVID-19/default.aspx

15. http://www.ipharminc.com/press-release/2020/4/20/screening-of-11552-compounds-identifies-innovation-pharmaceuticals-brilacidin-as-one-of-the-most-promising-potential-inhibitors-of-the-novel-coronavirus

16. https://finance.yahoo.com/news/nanoviricides-president-dr-anil-diwan-101500773.html

17. https://www.redhillbio.com/RedHill/Templates/showpage.asp?DBID=1&LNGID=1&TMID=178&FID=2432&PID=0&IID=15261

18. https://www.bold-therapeutics.com/news-post?Bold+Therapeutics+and+the+University+of+Ottawa+Initiate+Research+Partnership+to+Study+BOLD-100+in+the+Treatment+of+COVID-19

19. https://www.apeiron-biologics.com/wp-content/uploads/2020/04/20200402_APEIRON_Phase-2-EU-trial_APN01_ENG.pdf

20.

Expand

BIT are in with a good chance for COVID but their strength as a biotech lies in a variety of compounds they have for COVID/AIDS/HEP B HEP C... All they need is a good large Pharma to grab them and realise their value.. sure someone must have their eye on them!!!!!! I know i would if i had the money to buy them!!!!

Originally posted by shareman: ↑

Long term, I really hope BIT’s pre-clinical antiviral portfolio proves valuable.

However, in my view, it is unlikely that BIT will have a big (or any) role to play in the current pandemic.

Even if they get a positive hit for SARS-CoV-2 in a lab, this is likely a very long way off (especially if the hits only involve compounds other than BIT225) from having a commercialised product able to treat COCID-19 patients in the clinic. If BIT announces a positive hit in the lab for SARS-CoC-2, no doubt some people will rush in and reflexively buy and there will be a spike in the share price.

Unless the results are beyond spectacular, it is likely the share price will drift downwards after this spike (as it has done countless times in the past) as:
- traders exit
- people realise the competition in the COVID-19 treatment space is enormous; and
- it becomes clear the probability of BIT commercialising a product for the current pandemic is low at best.

For long-term value investors, it is always critically important to understand the competitive landscape before making an investment decision. Below is a small fraction of the many treatments under development for COVID-19 that current and prospective long-term BIT investors should make themselves familiar with.

No doubt if you went to the local stock market message boards (i.e. hotcopper equivalents) in the various countries where these companies are based, posters/traders/rampers would be writing just as confidently about how “company X” is a sure thing as posters on hotcopper do about BIT.

1. https://ir.moleculin.com/press-releases/detail/162/moleculin-announces-active-compound-in-wp1122-reduces

2. https://www.abcellera.com/news/2020-03-abcellera-and-lilly-codevelopment

3. https://www.prnewswire.com/news-releases/fda-clears-the-way-for-ridgeback-biotherapeutics-to-begin-human-testing-of-a-promising-potential-treatment-for-covid-19-301036307.html

4. https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-important-advances-novel-covid-19-antibody

5. http://www.oyageninc.com/wordpress/wp-content/uploads/2020/03/OyaGen-Press-for-03102020.pdf

6. https://investors.vir.bio/news-releases/news-release-details/samsung-biologics-and-vir-biotechnology-enter-agreement-large

7. https://investors.alnylam.com/press-release?id=24656

8. https://www.wsj.com/articles/supercomputers-help-researchers-speed-drug-discovery-for-covid-19-11586888735

9. https://www.immunic-therapeutics.com/2020/04/21/immunic-inc-reports-that-imu-838-a-selective-oral-dhodh-inhibitor-has-demonstrated-preclinical-activity-against-sars-cov-2-and-explores-plans-for-a-phase-2-clinical-trial-in-covid-19-patients/

10. https://www.beronigroup.com/2020/03/13/beroni-group-advances-research-and-development-of-medical-solution-for-coronavirus-covid-19/

11. https://www.beyondspringpharma.com/pressreleases/info.aspx?itemid=2212

12. https://www.cocrystalpharma.com/news/press-releases/detail/91/cocrystal-pharma-expands-exclusive-license-agreement-with

13. https://www.distributedbio.com/covid19

14. https://www.enanta.com/investors/news-releases/press-release/2020/Enanta-Pharmaceuticals-Announces-Efforts-to-Discover-a-Treatment-for-the-Novel-Coronavirus-Disease-COVID-19/default.aspx

15. http://www.ipharminc.com/press-release/2020/4/20/screening-of-11552-compounds-identifies-innovation-pharmaceuticals-brilacidin-as-one-of-the-most-promising-potential-inhibitors-of-the-novel-coronavirus

16. https://finance.yahoo.com/news/nanoviricides-president-dr-anil-diwan-101500773.html

17. https://www.redhillbio.com/RedHill/Templates/showpage.asp?DBID=1&LNGID=1&TMID=178&FID=2432&PID=0&IID=15261

18. https://www.bold-therapeutics.com/news-post?Bold+Therapeutics+and+the+University+of+Ottawa+Initiate+Research+Partnership+to+Study+BOLD-100+in+the+Treatment+of+COVID-19

19. https://www.apeiron-biologics.com/wp-content/uploads/2020/04/20200402_APEIRON_Phase-2-EU-trial_APN01_ENG.pdf

20.

Expand

(20min delay)
Last 3.0¢		Change 0.000(0.00%)		Mkt cap ! $27.06M

Open	High	Low	Value	Volume
3.0¢	3.0¢	3.0¢	$5.252K	175.9K

No.	Vol.	Price($)
2	707862	0.029
4	304631	0.027
4	3204659	0.026
5	640000	0.025
1	140000	0.024

Price($)	Vol.	No.
0.030	79328	3
0.031	99129	1
0.032	563492	3
0.033	100000	1
0.034	100000	1

COVID19 - competitive landscape, page-2

Emerald & Azure score Digger & Dealer awards

Hazer Group reports ten days of continuous operation at graphite-manufacturing test facility

True North increases silver metal at QLD's Vero deposit by 20%

From the Floor with Federal Opposition Leader Peter Dutton at Diggers & Dealers 2024

Trek Metals jumps 5% as gold & REE drill run kicks off at Christmas Creek in the Kimberley

Week 32 Wrap: AI is clearly overhyped – but did we see ‘bubble’ burst already? Plus RBA decision; Japan’s wild week & Google ruling

Bitcoin: Current State of Play & Where to Next | Swyftx

Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress

Dale Gillham's weekly wrap: picking resilient stocks in a volatile global market

Revolutionary inverter technology leads the clean energy charge

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

COVID19 - competitive landscape, page-2

Top Stories

Emerald & Azure score Digger & Dealer awards

Hazer Group reports ten days of continuous operation at graphite-manufacturing test facility

True North increases silver metal at QLD's Vero deposit by 20%

From the Floor with Federal Opposition Leader Peter Dutton at Diggers & Dealers 2024

Trek Metals jumps 5% as gold & REE drill run kicks off at Christmas Creek in the Kimberley

Week 32 Wrap: AI is clearly overhyped – but did we see ‘bubble’ burst already? Plus RBA decision; Japan’s wild week & Google ruling

Bitcoin: Current State of Play & Where to Next | Swyftx

Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress

Dale Gillham's weekly wrap: picking resilient stocks in a volatile global market

Revolutionary inverter technology leads the clean energy charge

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News